Condition (MeSH)
Dysplastic Nevus Syndrome
ClinicalTrials.gov lists 23 trials for Dysplastic Nevus Syndrome or a narrower condition beneath it. Orlucent, Inc has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
23 of the 23 trials are tagged with Dysplastic Nevus Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Dysplastic Nevus Syndrome trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2023 | 2 |
| 2022 | 1 |
| 2020 | 2 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 1 |
| 2016 | 1 |
| 2014 | 2 |
| 2013 | 2 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Dysplastic Nevus Syndrome trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Not applicable | 3 |
| Observational | 16 |
How many Dysplastic Nevus Syndrome trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 6 |
| Active, not recruiting | 1 |
| Completed | 11 |
| Terminated | 1 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Dysplastic Nevus Syndrome trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Orlucent, Inc | 3 |
| National Cancer Institute (NCI) | 2 |
| Immunovia, Inc. | 1 |
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state) | 1 |
| Single agent, adjuvant anti-PD1 therapy | 1 |
| data collection | 1 |
| Secretin | 1 |
| 20% betulinic acid ointment | 1 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Dysplastic Nevus Syndrome? (16)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Dysplastic/Clark naevus in the era of molecular pathology. | The Australasian journal of dermatology | 2019 | Yes |
| Risks of Melanoma and Other Cancers in Melanoma-Prone Families over 4 Decades. | The Journal of investigative dermatology | 2018 | Yes |
| A prospective study evaluating the utility of a 2-mm biopsy margin for complete removal of histologically atypical (dysplastic) nevi. | Journal of the American Academy of Dermatology | 2017 | Yes |
| Association of genetic variants in CDK6 and XRCC1 with the risk of dysplastic nevi in melanoma-prone families. | The Journal of investigative dermatology | 2014 | Yes |
| Dysplastic nevi and melanoma. | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology | 2013 | Yes |
Showing 5 of 16 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.